Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBorovcanin, Milica-
dc.contributor.authorRadosavljevic, Gordana-
dc.contributor.authorPantic, Jelena-
dc.contributor.authorMilovanovic, Jelena-
dc.contributor.authorMijailovic, Natasa-
dc.contributor.authorArsenijevic A.-
dc.contributor.authorArsenijevic, Nebojsa-
dc.description.abstractThe role of the Galectin-3 (Gal-3) has already been explored in various somatic diseas-es, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegener-ation, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a “second hit” later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia.-
dc.relation.ispartofCurrent Topics in Medicinal Chemistry-
dc.titleContrasting roles of the galectin-3 in the schizophrenia onset, clinical presentation, and somatic comorbidity-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
  Restricted Access
29.86 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.